Anti-Tumor Activity of Atractylenolide I in Human Colon Adenocarcinoma In Vitro.
Ka Woon Karen ChanHau Yin ChungWing Shing HoPublished in: Molecules (Basel, Switzerland) (2020)
Atractylodes macrocephala is known to exhibit multi-arrays of biologic activity in vitro. However, detail of its anti-tumor activity is lacking. In this study, the effects of atractylenolide I (AT-I), a bio-active compound present in Atractylodes macrocephala rhizome was studied in the human colorectal adenocarcinoma cell line HT-29. The results showed that AT-I induced apoptosis of human colon cancer cells through activation of the mitochondria-dependent pathway. The IC50 of AT-I was 277.6 μM, 95.7 μM and 57.4 μM, after 24, 48 and 72 h of incubation with HT-29, respectively. TUNEL and Annexin V-FITC/PI double stain assays showed HT-29 DNA fragmentation after cell treatment with various AT-I concentrations. Western blotting analysis revealed activation of both initiator and executioner caspases, including caspase 3, caspase 7, and caspase 9, as well as PARP, after HT-29 treatment with AT-I via downregulation of pro-survival Bcl-2, and upregulation of anti-survival Bcl-2 family proteins, including Bax, Bak, Bad, Bim, Bid and Puma. The studies show for the first time that AT-I is an effective drug candidate towards the HT-29 cell.
Keyphrases
- induced apoptosis
- endothelial cells
- signaling pathway
- endoplasmic reticulum stress
- cell death
- single cell
- oxidative stress
- squamous cell carcinoma
- pluripotent stem cells
- cell proliferation
- rheumatoid arthritis
- dna damage
- high throughput
- emergency department
- stem cells
- south africa
- single molecule
- combination therapy
- dna repair
- bone marrow